Compass Pathways' depression treatment meets main goal in late‑stage study
ReutersFeb 17, 2026 11:37 AM
Feb 17 (Reuters) - Drug developer Compass Pathways CMPS.O said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
The Magnificent Seven: What They Are, How They Performed in 2025, and Which Will Be the Best in 2026?
TradingKey - The Magnificent Seven refers to the seven best tech stocks in 2023. These are Apple (AAPL), Microsoft (MSFT), Alphabet (GOOG) (GOOGL), Amazon (AMZN), Nvidia (NVDA), Meta Platforms (META), and Tesla (TSLA). These technology titans are developing products related to Artificial IntelligencTradingKey
13 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
Thu, Feb 12
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
